Glaukos Corp (GKOS)

$118.14 +0.67 (0.57%)
Market Cap 6.86B
Revenue (ttm) 383.48M
Net Income (ttm) -146.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -38.17%
Debt to Equity Ratio 0.00
Volume 501,592
Avg Vol 811,388
Day's Range N/A - N/A
Shares Out 57.44M
Stochastic %K 6%
Beta 0.67
Analysts Strong Sell
Price Target $132.71

Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patient...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 367 9600
Fax: 949 367 9984
Address:
One Glaukos Way, Aliso Viejo, United States
Kingofstocks0001
Kingofstocks0001 Feb. 2 at 3:33 PM
$GKOS great growth
0 · Reply
Alex19949
Alex19949 Jan. 29 at 5:25 PM
$GKOS No dominant trend
0 · Reply
ZacksResearch
ZacksResearch Jan. 29 at 2:44 PM
$GKOS up 32.2% in 6 months — but can it sustain the momentum? 💡 🔹 Positioned for growth with interventional glaucoma shift 🔹 Synergies between iDose TR & iStent infinite boosting prospects 🔹 Long-term leverage despite short-term margin pressure Is this a long-term winner? Full analysis here 👉 https://www.zacks.com/stock/news/2825023/heres-why-you-should-retain-glaukos-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2825023-body-30881&ADID=SYND_STOCKTWITS_TWEET_2_2825023_BODY_30881
0 · Reply
ZacksResearch
ZacksResearch Jan. 29 at 1:44 PM
Hold onto $GKOS — this story isn’t done yet. 👀 Glaukos is positioned for growth as interventional glaucoma adoption expands, iDose and iStent synergies build, and scale drives operating leverage — even with margin pressure in the mix. That’s a long-term setup investors shouldn’t ignore. See why retaining GKOS still makes sense right now 👉 https://www.zacks.com/stock/news/2825023/heres-why-you-should-retain-glaukos-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2825023-teaser-30877&ADID=SYND_STOCKTWITS_TWEET_2_2825023_TEASER_30877
0 · Reply
notreload_ai
notreload_ai Jan. 28 at 2:58 PM
$GKOS receives FDA approval allowing patients to receive multiple iDose TR treatments for glaucoma management, expanding treatment options. https://notreload.xyz/fda-approves-repeat-treatment-for-idose-tr-glaucoma-implant/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 27 at 11:57 PM
$GKOS RSI: 56.57, MACD: 3.5246 Vol: 5.66, MA20: 115.79, MA50: 109.91 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Kingofstocks0001
Kingofstocks0001 Jan. 27 at 4:24 PM
$GKOS about to fly
0 · Reply
ZemoriSwings
ZemoriSwings Jan. 26 at 6:49 PM
$GKOS
0 · Reply
JFDI
JFDI Jan. 26 at 6:19 PM
$GKOS prolly worth stalking
0 · Reply
IN0V8
IN0V8 Jan. 22 at 3:37 PM
$GKOS Stifel raises target price to $160 from $115
1 · Reply
Latest News on GKOS
Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards

Feb 3, 2026, 10:00 AM EST - 10 hours ago

Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards

ACAD AI CNS FSV KTOS MSCI NTRA

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

Jan 29, 2026, 10:30 PM EST - 4 days ago

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

ABBV ABVX CVLT FIX FTAI GMAB HLI

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

Jan 28, 2026, 7:00 AM EST - 6 days ago

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17

Jan 20, 2026, 7:00 AM EST - 14 days ago

Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17

Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 11:55 PM EST - 20 days ago

Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

Jan 13, 2026, 4:05 PM EST - 21 days ago

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Dec 16, 2025, 7:00 AM EST - 7 weeks ago

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Glaukos Corporation (GKOS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 5:23 PM EST - 2 months ago

Glaukos Corporation (GKOS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Glaukos Corporation (GKOS) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 1:21 PM EST - 3 months ago

Glaukos Corporation (GKOS) Presents at UBS Global Healthcare Conference 2025 Transcript

Glaukos Announces Participation in Upcoming Investor Conferences

Nov 3, 2025, 7:00 AM EST - 3 months ago

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Corporation (GKOS) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 12:06 AM EDT - 3 months ago

Glaukos Corporation (GKOS) Q3 2025 Earnings Call Transcript

Glaukos Announces Third Quarter 2025 Financial Results

Oct 29, 2025, 4:05 PM EDT - 3 months ago

Glaukos Announces Third Quarter 2025 Financial Results

US FDA approves Glaukos' new eye therapy

Oct 20, 2025, 7:10 AM EDT - 3 months ago

US FDA approves Glaukos' new eye therapy

Glaukos Announces FDA Approval of Epioxa™

Oct 20, 2025, 7:00 AM EDT - 3 months ago

Glaukos Announces FDA Approval of Epioxa™

Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

Oct 14, 2025, 7:00 AM EDT - 4 months ago

Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29

Oct 8, 2025, 7:00 AM EDT - 4 months ago

Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29

Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

Sep 25, 2025, 4:05 PM EDT - 4 months ago

Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Aug 13, 2025, 7:00 AM EDT - 6 months ago

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 5:15 AM EDT - 6 months ago

Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript

Glaukos Announces Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 6 months ago

Glaukos Announces Second Quarter 2025 Financial Results

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Jul 9, 2025, 7:00 AM EDT - 7 months ago

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

Jun 25, 2025, 4:05 PM EDT - 7 months ago

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

Jun 25, 2025, 7:00 AM EDT - 7 months ago

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 10:05 PM EDT - 9 months ago

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Glaukos Announces First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 9 months ago

Glaukos Announces First Quarter 2025 Financial Results

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Apr 29, 2025, 11:30 AM EDT - 10 months ago

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

ACLX BSX DHR INSM ISRG LLY RDNT

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 23, 2025, 7:00 AM EDT - 10 months ago

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Glaukos Announces the Release of its 2024 Sustainability Report

Apr 16, 2025, 7:00 AM EDT - 10 months ago

Glaukos Announces the Release of its 2024 Sustainability Report

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

Apr 9, 2025, 7:00 AM EDT - 10 months ago

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Mar 11, 2025, 7:00 AM EDT - 11 months ago

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Feb 24, 2025, 9:12 AM EST - 1 year ago

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Feb 24, 2025, 7:00 AM EST - 1 year ago

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Feb 21, 2025, 10:27 AM EST - 1 year ago

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript

Feb 21, 2025, 4:29 AM EST - 1 year ago

Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 20, 2025, 4:05 PM EST - 1 year ago

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Jan 23, 2025, 7:00 AM EST - 1 year ago

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Jan 14, 2025, 4:05 PM EST - 1 year ago

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday

Dec 31, 2024, 8:59 AM EST - 1 year ago

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Dec 23, 2024, 7:00 AM EST - 1 year ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Dec 21, 2024, 7:04 AM EST - 1 year ago

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Dec 17, 2024, 7:00 AM EST - 1 year ago

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Dec 2, 2024, 2:29 PM EST - 1 year ago

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

ISRG NVRO SYK

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

Nov 5, 2024, 12:21 PM EST - 1 year ago

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 11:03 PM EST - 1 year ago

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Glaukos Announces Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

Glaukos Announces Third Quarter 2024 Financial Results

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Oct 16, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

Sep 23, 2024, 1:30 AM EDT - 1 year ago

Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 8:57 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript

Kingofstocks0001
Kingofstocks0001 Feb. 2 at 3:33 PM
$GKOS great growth
0 · Reply
Alex19949
Alex19949 Jan. 29 at 5:25 PM
$GKOS No dominant trend
0 · Reply
ZacksResearch
ZacksResearch Jan. 29 at 2:44 PM
$GKOS up 32.2% in 6 months — but can it sustain the momentum? 💡 🔹 Positioned for growth with interventional glaucoma shift 🔹 Synergies between iDose TR & iStent infinite boosting prospects 🔹 Long-term leverage despite short-term margin pressure Is this a long-term winner? Full analysis here 👉 https://www.zacks.com/stock/news/2825023/heres-why-you-should-retain-glaukos-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2825023-body-30881&ADID=SYND_STOCKTWITS_TWEET_2_2825023_BODY_30881
0 · Reply
ZacksResearch
ZacksResearch Jan. 29 at 1:44 PM
Hold onto $GKOS — this story isn’t done yet. 👀 Glaukos is positioned for growth as interventional glaucoma adoption expands, iDose and iStent synergies build, and scale drives operating leverage — even with margin pressure in the mix. That’s a long-term setup investors shouldn’t ignore. See why retaining GKOS still makes sense right now 👉 https://www.zacks.com/stock/news/2825023/heres-why-you-should-retain-glaukos-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2825023-teaser-30877&ADID=SYND_STOCKTWITS_TWEET_2_2825023_TEASER_30877
0 · Reply
notreload_ai
notreload_ai Jan. 28 at 2:58 PM
$GKOS receives FDA approval allowing patients to receive multiple iDose TR treatments for glaucoma management, expanding treatment options. https://notreload.xyz/fda-approves-repeat-treatment-for-idose-tr-glaucoma-implant/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 27 at 11:57 PM
$GKOS RSI: 56.57, MACD: 3.5246 Vol: 5.66, MA20: 115.79, MA50: 109.91 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Kingofstocks0001
Kingofstocks0001 Jan. 27 at 4:24 PM
$GKOS about to fly
0 · Reply
ZemoriSwings
ZemoriSwings Jan. 26 at 6:49 PM
$GKOS
0 · Reply
JFDI
JFDI Jan. 26 at 6:19 PM
$GKOS prolly worth stalking
0 · Reply
IN0V8
IN0V8 Jan. 22 at 3:37 PM
$GKOS Stifel raises target price to $160 from $115
1 · Reply
erevnon
erevnon Jan. 22 at 2:57 PM
Stifel maintains Glaukos $GKOS at Buy and raises the price target from $115 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Stackdoe1
Stackdoe1 Jan. 16 at 7:26 PM
$GKOS $150
0 · Reply
Kingofstocks0001
Kingofstocks0001 Jan. 14 at 4:29 PM
$GKOS This is undervalued. Easily will reach $170 in 3 months. Wait for the 70% gain.
0 · Reply
notreload_ai
notreload_ai Jan. 14 at 4:08 PM
$GKOS shares fell after Q4 iDose sales growth disappointed investors, though the company maintained its 2026 revenue guidance of $600-620 million. https://notreload.xyz/glaukos-stock-falls-on-slower-idose-product-growth-in-q4/
0 · Reply
EmoDaddy
EmoDaddy Jan. 14 at 3:57 PM
$GKOS debt free is the way to be!
0 · Reply
medguy
medguy Jan. 14 at 2:53 PM
Thanks, out $GKOS for a quick gain.
1 · Reply
medguy
medguy Jan. 14 at 2:32 PM
Looking for bounce $TCOM $WFC $GKOS
0 · Reply
OpenOutcrier
OpenOutcrier Jan. 14 at 1:59 PM
$GKOS (-14.3% pre) Glaukos falls on preliminary Q4 iDose sales https://ooc.bz/l/89665
0 · Reply
erevnon
erevnon Jan. 14 at 10:58 AM
Needham reiterates Glaukos $GKOS at Buy and maintains the price target at https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
DonCorleone77
DonCorleone77 Jan. 14 at 2:12 AM
$TGTX $SPT $RMCF $GKOS $HNRG AFTER-HOURS MOVERS: Currently Higher After Earnings: - Phoenix Education Partners (PXED) up 0.9% Currently Also Higher: - TG Therapeutics (TGTX) up 7.0% after Q4 pre-announcement, FY26 guidance - Sprout Social (SPT) up 4.9% after insider buy Currently Lower After Earnings: - Concrete Pumping (BBCP) down 0.7% - Rocky Mountain Chocolate Factory (RMCF) down 2.8% Currently Also Lower: - Glaukos (GKOS) down 12.0% after Q4 pre-announcement - Hallador Energy (HNRG) down 6.6% after equity offering
0 · Reply
Stockmull71
Stockmull71 Jan. 13 at 11:08 PM
$GKOS will be back over 105 within a week
1 · Reply
RazorbackAJ
RazorbackAJ Jan. 13 at 10:37 PM
$GKOS Terrible results - shorting here with trailing stop at $108. Follow for such precise entries with stops.
0 · Reply